Talphera Inc (TLPH)
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies intended for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized nafamostat formulation being evaluated under an investigational device exemption as an anticoagulant for the extracorporeal circuit. The pipeline also includes LTX-608, a nafamostat formulation designed for direct intravenous infusion and being studied for potential use in several indications, including antiviral applications, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. In addition, the company is developing Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates. Formerly known as AcelRx Pharmaceuticals, Inc., the company adopted the Talphera name in January 2024. Founded in 2005, Talphera is based in San Mateo, California, and its common stock is listed on NASDAQ under the symbol TLPH.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TLPH
|
$1.04
|
-21.8% Downside
|
Overvalued
|
$3.17
|
138.3% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-4.8x
|
3.7x
|
68,507.5x
|
66.951 M
|
53.899 M
|
8.8%
|
52.0%
|
-19.5
|
—
|
79.2%
|
